CommercialPrior AuthMedium impact
Eptinezumab-jjmr (Vyepti®)
BCBS Tennessee·TN · Neurology, General Practice, Pain Management·Medical Policy
Effective date
Oct 31, 2026
We identified it
Aug 13, 2026
Summary
BlueCross BlueShield of Tennessee is implementing a new medical policy for Eptinezumab-jjmr (Vyepti®) for migraine prevention, effective 10/31/26. The policy establishes prior authorization requirements, coverage criteria for chronic and episodic migraines, documentation requirements, and prohibits concurrent use with other CGRP antagonists. NOTE: This policy explicitly states 'Does Not Apply to BlueCare' and has a future effective date with a 'Do Not Implement until 10/31/26' instruction.
Action Required
By 10/31/2026: Billing team must prepare to implement prior authorization requirements for Vyepti (Eptinezumab-jjmr) claims. (1) Update billing system to flag all Vyepti requests for prior auth review before processing. (2) Ensure providers submit required documentation with prior auth requests: for initial requests, include chart notes documenting migraine headache days/month and evidence of failed trials (≥2 oral preventatives for ≥2 months) or contraindications; for continuation requests, include documentation of positive clinical response (reduction in headache frequency/intensity). (3) Configure system to deny claims for concurrent use of Vyepti with other CGRP antagonists. (4) Verify member eligibility requirements: age ≥18, diagnosis of chronic migraine (15-26 headache days/month, ≥8 migraine days) OR episodic migraine (4-14 headache days/month, ≥4 migraine days). (5) Educate providers that initial authorization is for 6 months; continuation authorization is for 12 months. (6) DO NOT implement for BlueCare members. Claims lacking proper prior authorization or required documentation will be denied.